A Smart, Fully Subcutaneous Distraction System to Improve Outcomes in Patients with Congenital or Acquired Craniofacial Differences

智能、全皮下牵引系统可改善先天性或后天性颅面差异患者的治疗效果

• 批准号: 10696721
• 负责人: Jessica DesNoyer
• 金额: $ 89.25万
• 依托单位: OSTIIO LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-14 至 2025-09-13
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10696721
• 关键词: Address; Adopted; Adoption; Affect; Analgesics; Anesthesia procedures; Animal Model; Animals; Autopsy; Bilateral; Biological; Blinded; Blood Transfusion; Bone Growth; Bone Regeneration; Bone structure; Breathing; Buffers; Caregivers; Caring; Cephalic; Cicatrix; Clinic; Clinical; Communication; Coupling; Craniofacial Abnormalities; Defect; Development; Device Designs; Devices; Distraction Osteogenesis; Ensure; Environment; Evaluation; Exhibits; Exposure to; Family suidae; Freezing; Generations; Growth; Hearing; Histologic; Home; Housing; Immersion; Impairment; Implant; Infection; Length of Stay; Liquid substance; Magnetism; Mandible; Manuals; Mastication; Measures; Miniature Swine; Modality; Monitor; Neurologic; Newborn Infant; Operative Surgical Procedures; Osteotomy; Outcome; Output; Pain; Particulate; Patient risk; Patient-Focused Outcomes; Patients; Phase; Physicians; Process; Protocols documentation; Radiation exposure; Risk; Safety; Saline; Sampling; Shapes; Site; Skeleton; Skin; Specific qualifier value; Specimen; Speech; Surgeon; System; Systems Integration; Techniques; Technology; Testing; Therapeutic; Time; Tissues; Torque; Training; Treatment Failure; Treatment Protocols; Validation; Vision; Visual; biomaterial compatibility; bone; craniofacial; craniomaxillofacial; cranium; design; distraction; effectiveness testing; experience; functional restoration; implantation; improved; improved outcome; in vivo; manufacture; non-compliance; novel strategies; operation; patient population; performance tests; prevent; prototype; reconstruction; remote monitoring; seal; skeletal; stem; subcutaneous; success; wireless communication

SUMMARY / ABSTRACT Each year, ~200,000 newborns worldwide, 80-85% of whom require surgical intervention, are afflicted with congenital conditions that cause impaired growth of the skull or mandible, leading to abnormalities that affect breathing, hearing, speech, visual function, neurologic development, and mastication. Unfortunately, current surgical treatments, including endoscopic surgery, open reconstruction, and distraction osteogenesis (DO), suffer inherent drawbacks, impacting outcomes. A better solution is needed for this vulnerable patient population. DO is a widely recognized treatment modality that harnesses the body’s natural ability to regenerate bone in order to correct skeletal deficiencies and defects. While still emerging for craniomaxillofacial (CMF) applications, surgeons have shown the utility of DO for restoring functional discrepancies in patients with craniofacial differences. The technique of DO involves surgical placement of one or more distractors, which are devices used to slowly separate two opposing bony fragments at an osteotomy site, to gradually lengthen and reshape the affected bone and stimulate new bone growth. However, DO is not without shortcomings. First, all current distractors have an external component for manual expansion. The external component significantly increases patient risk for complications such as infection (35%), device dislodgement (3.0%), increased analgesic use, and scarring (15.6%). Second, since the burdensome responsibility for manual expansion lies with the caregiver, treatment noncompliance (4.7%) is a serious issue, introducing vulnerabilities ranging from inconsistent device expansion to complete treatment failure. Therefore, DO necessitates extensive physician clinic time and patient radiation exposure to monitor therapeutic progress and thus has not been widely adopted in the CMF skeleton despite recognition of potential advantages over endoscopic surgery (narrower indication for use) and open reconstruction (more invasive, longer anesthesia time, higher blood transfusion rate, longer hospital stay). The Ostiio distraction system addresses many of the issues associated with DO treatment as the first fully subcutaneous, programmable DO system for the CMF skeleton. At a high level, the Ostiio distraction system leverages magnetic coupling to transfer torque from the hand-held driver (HHD) to the implant, thereby expanding the implant in a contactless fashion. This novel approach will markedly reduce infection, scarring, and manipulation noncompliance. In addition, because the design uniquely permits wireless communication between the implant and HHD, it will enable physicians to better control and monitor treatment progress. This Phase II proposal aims to a) achieve design freeze of the integrated Ostiio distraction system, incorporating design improvements to ensure device biocompatibility and functionality throughout active distraction, and b) demonstrate the system can be used safely and effectively to perform a complete distraction protocol in vivo in standard animal model. Successful demonstration of this outcome will satisfy key validation performance testing requirements for FDA submission and 510(k) clearance and open a path to widespread clinical adoption.

摘要/摘要